Evidence map›Paper›PMID 21664945›Full record

ReviewMolecular and cellular endocrinology2012

Structural features discriminate androgen receptor N/C terminal and coactivator interactions.

Emily B Askew, John T Minges, Andrew T Hnat, Elizabeth M Wilson

Abstract readReview
In one paragraph

Review in Molecular and cellular endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Androgen Action in the Ovary.Frontiers in endocrinology · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.International journal of biological sciences · 2014
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Emily B AskewLaboratories for Reproductive Biology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599-7500, USA. askewe@ecu.edu
John T Minges
Andrew T Hnat
Elizabeth M Wilson
University of North Carolina at Chapel Hill · USUNC Lineberger Comprehensive Cancer Center

Funding

Tumor stem cells in androgen independent prostate cancerP01CA077739 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FRENCH, FRANK S, MOHLER, JAMES L · 1998 to 2014
$16.8M
TESTIS SPECIFIC HISTONE BINDING PROTEIN (NASP)U54HD035041 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PETRUSZ, PETER · 1997 to 2011
$16.1M
ANDROGEN RECEPTOR REGULATION OF REPRODUCTIVE FUNCTIONR01HD016910 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILSON, ELIZABETH M. · 1985 to 2010
$2.8M
ANDROGEN RECEPTOR REGULATION OF REPRODUCTIVE FUNCTIONR37HD016910 · NICHD · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI WILSON, ELIZABETH M. · 1993 to 2002
$1.1M
NCI NIH HHS P01 CA077739NCI NIH HHS P01-CA77739NICHD NIH HHS HD16910NICHD NIH HHS R01 HD016910NICHD NIH HHS R37 HD016910NICHD NIH HHS U54 HD035041NICHD NIH HHS U54-HD35041
6 · The paper itself

Abstract

Human androgen receptor (AR) transcriptional activity involves interdomain and coactivator interactions with the agonist-bound AR ligand binding domain (LBD). Structural determinants of the AR NH(2)- and carboxyl-terminal interaction between the AR NH(2)-terminal FXXLF motif and activation function 2 (AF2) in the LBD were shown previously by crystallography. In this report, we provide evidence for a region in AR LBD helix 12 outside the AF2 binding cleft that facilitates interactions with the FXXLF and LXXLL motifs. Mutagenesis of glutamine 902 to alanine in AR LBD helix 12 (Q902A) disrupted AR FXXLF motif binding to AF2, but enhanced coactivator LXXLL motif binding. Functional compensation for defective FXXLF motif binding by AR-Q902A was suggested by the slower dissociation rate of bound androgen. Functional importance of glutamine 902 was indicated by the charged residue germline mutation Q902R that caused partial androgen insensitivity, and a similar somatic mutation Q902K reported in prostate cancer, both of which increased the androgen dissociation rate and decreased AR transcriptional activity. High affinity equilibrium androgen binding was retained by alanine substitution mutations at Tyr-739 in AR LBD helix 5 or Lys-905 in helix 12 structurally adjacent to AF2, whereas transcriptional activity decreased and the androgen dissociation increased. Deleterious effects of these loss of function mutations were rescued by the helix stabilizing AR prostate cancer somatic mutation H874Y. Sequence NH(2)-terminal to the AR FXXLF motif contributed to the AR NH(2)- and carboxyl-terminal interaction based on greater AR-2-30 FXXLF motif peptide binding to the agonist-bound AR LBD than a shorter AR-20-30 FXXLF motif peptide. We conclude that helix 12 residues outside the AF2 binding cleft modulate AR transcriptional activity by providing flexibility to accommodate FXXLF or LXXLL motif binding.

Indexed as

Amino Acid MotifsAmino Acid SubstitutionAndrogensAnimalsBinding SitesCrystallography, X-RayDihydrotestosteroneGene Expression RegulationHumansModels, MolecularNuclear Receptor Coactivator 2Protein Structure, TertiaryReceptors, AndrogenSurface PropertiesTranscriptional ActivationAndrogensDihydrotestosteroneNuclear Receptor Coactivator 2Receptors, Androgen

Identifiers

PMID21664945
PMCPMC3199032
OpenAlexW2136906481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.